$0.07
(Market cap
$842 Mln
Revenue (TTM)
$39 Mln
P/E Ratio
--
P/B Ratio
2.1
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-16.4 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
-1.3
-
Debt to Equity
-2
-
Book Value
$--
-
EPS
$--
-
Face value
--
-
Shares outstanding
208,947,924
10 Years Aggregate
CFO
€-328.01 Mln
EBITDA
€-347.07 Mln
Net Profit
€-350.39 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Inventiva Sa (IVA)
| -16.8 | -33.3 | -41.6 | 9.3 | 3.2 | -24.4 | -- |
|
BSE Sensex
| -10.8 | -0.6 | -1.7 | -8.5 | 6.4 | 7.6 | 11.0 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
|---|---|---|---|---|---|
|
Inventiva Sa (IVA)
| 117.3 | -52.3 | 1.3 | -67.3 | -5.8 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Inventiva Sa (IVA)
|
3.9 | 842.1 | 4.5 | -340.2 | -518.6 | 501.4 | -- | 2.1 |
| 23.0 | 12,015.6 | 19,358.3 | 944.7 | 9.6 | 5.5 | 11.9 | 0.8 | |
| 28.0 | 1,862.3 | 1,043.8 | 488.8 | -19.0 | 16 | 3.2 | 0.5 | |
| 1.8 | 160.6 | 2.8 | -49.2 | -86.4 | 764.8 | -- | 20.1 | |
| 35.0 | 1,798.3 | 29.6 | -24.0 | -- | 31.9 | -- | 65.0 | |
| 5.4 | 519.6 | 156.3 | -138.0 | -16.7 | -121.5 | -- | 6.1 |
Shareholding Pattern
View DetailsAbout Inventiva Sa (IVA)
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally. It... develops Lanifibranor, a novel peroxisome proliferator-activated receptor agonist that is in the NATiV3 Phase 3 clinical trial to treat adult patients with MASH; and Odiparcil for the treatment of patients with mucopolysaccharidoses. The company also develops TGF-ß, a pre-clinical program for the treatment of idiopathic pulmonary fibrosis. Inventiva S.A. was incorporated in 2011 and is headquartered in Daix, France. Read more
-
Co-Founder, Chief Scientific Officer, Deputy CEO & Director
Dr. Pierre Broqua Ph.D.
-
Co-Founder, Chief Scientific Officer, Deputy CEO & Director
Dr. Pierre Broqua Ph.D.
-
Headquarters
Daix
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Inventiva Sa (IVA)
What is the current share price of Inventiva Sa (IVA) Today?
The share price of Inventiva Sa (IVA) is $3.87 (NASDAQ) as of 12-Jun-2026 13:39 EDT. Inventiva Sa (IVA) has given a return of 3.21% in the last 3 years.
What is the current PB & PE ratio of Inventiva Sa (IVA)?
Since, TTM earnings of Inventiva Sa (IVA) is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
--
|
--
|
|
2024
|
--
|
--
|
|
2023
|
--
|
--
|
|
2022
|
--
|
--
|
|
2021
|
--
|
--
|
What is the 52 Week High and Low of Inventiva Sa (IVA)?
The 52-week high and low of Inventiva Sa (IVA) are Rs 7.98 and Rs 2.85 as of 13-Jun-2026.
What is the market cap of Inventiva Sa (IVA)?
Inventiva Sa (IVA) has a market capitalisation of $ 842 Mln as on 05-Jun-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Inventiva Sa (IVA)?
Before investing in Inventiva Sa (IVA), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.